Genotoxic chemicals exert their adverse effect through interaction with genetic material (DNA) of cells. Genotoxicity tests are designed to detect drugs which can induce genetic damage directly or indirectly by various mechanisms of action. Compounds identified as genotoxic in these tests have the potential to be human carcinogens and/or mutagens, and ultimately may induce cancer and/or heritable defects.

Genotoxicity Services

Genotoxicity testing of new chemical entities is an integral part of the drug development process and is a regulatory requirement prior to the approval of new drugs. By identifying genotoxicity at an early stage in drug discovery rather than during regulatory assessment, the likelihood of late stage failures is reduced.

Evotec and wholly owned subsidiary Cyprotex offer a range of early stage screening (non-GLP) and later stage regulatory (GLP) services to detect genotoxicity.

Discover more about our genotoxicity services:

Non-GLP Services

GLP Services

  • Bacterial Mutation Test (In Vitro Ames)
  • Mammalian Chromosome Aberration (In Vitro HPLA)
  • Rodent Micronucleus Test (In Vivo)
  • Mammalian Cell Micronucleus Test (In Vitro)

Cyprotex eStore

Order our services online.

Visit the Cyprotex eStore
Benjamin Park

Benjamin Park

Associate Principal Scientist

Logo Cyprotex white
Cyprotex enables and enhances the prediction of human exposure, clinical efficacy and toxicological outcome of a drug or chemical. By combining quality data from robust in vitro methods with contemporary in silico technology, we add value, context and relevance to the ADME-Tox data supplied to our partners in the pharmaceutical or chemical industries.